JPRN-UMIN000009790招募中4 期
Toyama antihypertensive therapy with Olmesartan in Post-Stroke patients (TOPS) study - Toyama antihypertensive therapy with Olmesartan in Post-Stroke patients (TOPS) study
niversity of Toyama0 个研究点目标入组 100 人开始时间: 2013年1月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Myocardial infarction, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, unknown type of stroke within previous 6 months (TIA can be registerd) Grade III hypertension (systolic BP>=180mmHg or diastolic BP>=110mmHg) Percutaneous or surgical coronary intervention (PCI, CABG etc.), severe heart failure within 6 months Percutaneous or surgical coronary intervention planned Persistent or permanent atrial fibrillation History of congenital heart disease, rheumatic heart disease, moderate or severe valvular heart disease Unstable angina, severe arrhythmia Pregnant, possible to pregnancy Not appropriate to long term observation Difficult to obtain consent because of minors or dementia etc.
研究者
相似试验
进行中（未招募）
1 期
Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.Irbesartan en el tratamiento del paciente hipertenso con síndrome metabólicoHypertension, nosEUCTR2005-000614-12-ESBristol Myers Squibb International Corporation540
进行中（未招募）
不适用
Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.Revised Protocol 2, incorporating Protocol Amendments 01 dated 09-Jan-06 & 02 dated 05-Oct-2006. And Protocol amendment 03 dated 24-Oct-2006 - Biomarkers Substudy.EUCTR2005-000614-12-DEBristol Myers Squibb International Corporation540
进行中（未招募）
不适用
Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.Treatment of hypertensive patients with metabolic syndromeMedDRA version: 6.1Level: HLGTClassification code 10057166EUCTR2005-000614-12-ITBRISTOL-M.SQUIBB540
进行中（未招募）
1 期
Seeking the ideal anti-hypertensive therapy in obesity-related hypertension. An open-label, single center, randomized clinical trial.obesity linked hypertensionMedDRA version: 19.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2016-000571-25-ESFundació Clinic per a la Recerca Biomèdica
已完成
3 期
Olmesartan in Essential HypertensionEssential HypertensionNCT00185172Sankyo Pharma Gmbh2,333